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Continuous venovenous hemodiafiltration (CVVHDF) using solutions designed to maintain hypernatremia is described in an
end-stage renal disease (ESRD) patient with cerebral edema (CE) due to an intracerebral hemorrhage (ICH). Hypernatremia was
readily achieved and maintained without complication. CVVHDF should be considered as an alternative treatment option in
ESRD patients with cerebral edema who require hypertonic saline therapy.

1. Introduction
Osmotherapy is an option for the treatment of cerebral
edema due to acute brain injury. It is used to prevent progression of CE and lower intracerebral pressure (ICP). Mannitol
and hypertonic saline (HTS) are the drugs currently available
for this purpose [1]. Mannitol would be inappropriate in a
patient with end-stage renal disease (ESRD) due to its accumulation in a patient without excretory function. Hypertonic
saline would be acceptable only as long as its accumulation
and the excess extracellular volume generated by the resulting
hypertonicity could be controlled. A patient with ESRD
is described who developed an ICH with subsequent CE
and was placed on continuous venovenous hemodiafiltration
(CVVHDF) using fluids specially designed to maintain a
hypertonic state with goal serum sodium of approximately
150–155 meq/L.

2. Case Report
The patient is a 45-year-old male admitted after developing
a headache, slurred speech, and left hemiparesis during his

routine hemodialysis treatment. A CT scan of the brain
showed a 4.4 × 2.5 cm area of hyperattenuation in the
right basal ganglia area, moderate edema associated with
the ICH, and mass eﬀect with a 2 mm right-to-left midline
shift. His admission serum sodium was 139 meq/L. He
had been on hemodialysis for the past 7 to 8 years. He
was known to be hepatitis C antibody and hepatitis B
antigen positive. He also had a history of hypertension
and asthma. The day after admission a repeat CT scan
demonstrated that the edema and mass eﬀect had increased
and that the midline shift had increased to 10 mm. Because of
compression on the third ventricle, mild hydrocephalus had
also developed. A ventriculostomy catheter was inserted the
day after admission. That same morning, he was started on
continuous venovenous hemodiafiltration (CVVHDF) using
regional citrate anticoagulation. Our standard CVVHDF
protocol is based on that of Mehta et al. [2] but uses a
fixed rate of citrate. The standard protocol has a dialysate
sodium of 117 meq/L and a predilution replacement fluid
sodium of 135 meq/L. This was adjusted to a dialysate
sodium of 127 meq/L and a predilution replacement fluid
sodium of 155 meq/L. In addition, shortly after the initiation
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of CVVHDF, the patient was given a 250 cc bolus of 3% saline
followed by an infusion at 100 cc/hr to quickly elevate his
serum sodium. The infusion was discontinued the next day,
and the patient was maintained on hypertonic CVVHDF.
CVVHDF was continued for a total of four days. Lab
values were frequently monitored. Minor adjustments to
the solutions were made to keep the serum sodium near
the goal of approximately 155 meq/L. Peak serum sodium
was 157 meq/L. Serum sodium was successfully maintained
in the goal range. Intracranial pressure and cerebral perfusion pressure were frequently monitored and were always
satisfactory. Unfortunately, the patient’s neurologic status
did not improve. After four days of CVVHDF, the decision
was made to allow the serum sodium to slowly normalize.
CVVHDF was stopped, and the patient was placed back on
intermittent hemodialysis. Dialysate sodium of 147 meq/L
was used for one hemodialysis treatment and then 145 meq/L
was used for the next treatment. The serum sodium came
down to 144 meq/L. Several followup head CT scans showed
no improvement. At that point, the family requested further
therapy be discontinued, and the patient expired shortly
thereafter.

3. Discussion
Osmotherapy is an eﬀective treatment option to control CE
and reduce intracranial pressure in patients with acute brain
injury. Mannitol and HTS are the usual drugs used. Both can
have significant side eﬀects. Mannitol has been reported to
cause a variety of electrolyte disturbances and acute renal
failure [3]. In an ESRD patient who is anuric, mannitol
could accumulate in the brain tissue and paradoxically
increase CE. HTS causes hypernatremia and extracellular
volume expansion and can cause metabolic acidosis and
hypokalemia among other side eﬀects [4]. HTS has been
shown to be eﬀective in patients resistant to mannitol therapy
[4, 5]. HTS may also have a beneficial eﬀect on mortality
in the treatment of raised ICP when compared to mannitol
[6]. It has been reported that serum tonicity as high as
365 mosm/l can be safely achieved with HTS therapy whereas
mannitol therapy is limited to a maximum of 320 mosm/l
[7]. When hypernatremia, whether or not a consequence of
osmotic therapy, was evaluated in patients in a neurologic
ICU, it was an independent predictor of mortality only when
the peak serum sodium exceeded 160 meq/L [8].
It has recently been suggested that continuous renal
replacement therapy, due to greater cardiovascular and
intracranial stability, is the preferred method to treat patients
with acute brain injury and renal failure [9]. We treated our
patient with CVVHDF using specifically prepared solutions.
Our pharmacy does not use commercially prepared solutions
but rather uses an automatic compounder to custom mix
the ordered solutions. Thus, it was straightforward for the
pharmacy to mix the requested solutions for hypertonic
CVVHDF. This simplified the patient’s regimen as the need
for a constant hypertonic saline drip was eliminated. We
observed no untoward eﬀects from the hypertonic dialysis,
and the serum sodium was readily maintained in the goal
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range. We are aware of only one similar report in the literature, that of Hofmann et al. using continuous venovenous
hemofiltration (CVVH) and that is only reported in abstract
form [10]. We feel that hypertonic CVVHDF should be
considered a reasonable treatment option for acute brain
injury in patients with renal failure.

4. Conclusion
CVVHDF with solutions designed to induce hypernatremia
was used to treat an ESRD patient with CE due to an
ICH. We were able to maintain the serum sodium at goal,
and no adverse eﬀects of the procedure were noted. We
suggest hypertonic CVVHDF be considered an option in
the treatment of ESRD patients with CE due to acute brain
injury.
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